title: 18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.
abstract: In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of 18F-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with 18F-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer.
authors: Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan. go242h@yahoo.co.jp
authors: Hideaki
authors: H
authors: Tsuyoshi
authors: Fumiko
authors: F
authors: Morishita
authors: Makoto
authors: M
authors: Orisaka
authors: Hidehiko
authors: H
authors: Okazawa
authors: Yoshio
authors: Y
authors: Yoshida
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015224:Dideoxynucleosides; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D049268:Positron-Emission Tomography; D012008:Recurrence; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D014408:Biomarkers, Tumor; D015224:Dideoxynucleosides; D003841:Deoxycytidine; C002854:alovudine; D000093542:Gemcitabine